Cefpimizole
| Cefpimizole | |
|---|---|
| Cefpimizole.svg | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Cefpimizole is a cephalosporin antibiotic used in the treatment of various bacterial infections. It belongs to the class of beta-lactam antibiotics, which are known for their broad-spectrum activity against both Gram-positive and Gram-negative bacteria.
Mechanism of Action[edit]
Cefpimizole works by inhibiting bacterial cell wall synthesis. It binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, which leads to the interruption of peptidoglycan synthesis. This results in the weakening of the cell wall and ultimately causes bacterial cell lysis and death.
Pharmacokinetics[edit]
Cefpimizole is administered intravenously or intramuscularly. After administration, it is distributed widely throughout the body, including into tissues and fluids. The drug is primarily excreted unchanged in the urine, which makes it effective for treating urinary tract infections.
Clinical Uses[edit]
Cefpimizole is used to treat a variety of infections, including:
- Respiratory tract infections
- Urinary tract infections
- Skin and soft tissue infections
- Intra-abdominal infections
Side Effects[edit]
Common side effects of cefpimizole include:
- Gastrointestinal disturbances such as nausea and diarrhea
- Allergic reactions, including rash and pruritus
- Hematological effects such as neutropenia and thrombocytopenia
Resistance[edit]
Bacterial resistance to cefpimizole can occur through several mechanisms, including the production of beta-lactamases, which can hydrolyze the beta-lactam ring of the antibiotic, rendering it ineffective. Resistance can also occur through alterations in PBPs or decreased permeability of the bacterial cell wall.
Related pages[edit]
-
Cefpimizole
